How much cost per yr is keytruda use in america?

Annual Cost of Keytruda in the US: Understanding the Pricing Landscape

What's the total cost of Keytruda each year?

According to recent reports, the annual cost of Keytruda (pembrolizumab) in the US can range from around $143,000 to over $250,000 per year, depending on various factors, such as the patient's insurance coverage, dosage, and administration [4].

How does the cost break down?

The cost of Keytruda involves several components:

* Wholesale acquisition cost (WAC): The average WAC for a 4-week supply of Keytruda is approximately $12,000 to $14,000 [1].
* Retail price: After applying rebates, discounts, and other adjustments, the retail price can drop, but patients still face out-of-pocket costs.
* Insurance coverage: Private insurance plans may cover a portion of the costs, but Medicare and Medicaid often have more restrictive coverage policies [2].

Why are costs so high?

Several factors contribute to the high costs of Keytruda:

* Biological complexity: Keytruda is a biosimilar, which requires complex production and distribution processes.
* Research and development: The development costs and time invested in discovering and obtaining regulatory approval for Keytruda drive up its price.
* Marketing and advertising: Companies spend millions on marketing and advertising their products, which gets factored into the final price.

What can patients do to reduce costs?

Patients and healthcare providers can explore various options to reduce Keytruda costs:

* Clinical trials: Some patients may be eligible to receive Keytruda at a reduced cost or for free through clinical trials.
* Insurance coverage: Patients can work with their healthcare providers and insurance companies to explore coverage options and potential copay assistance.
* Generic alternatives: As biosimilars become more prevalent, patients may have access to more affordable, comparable treatments.

By understanding the complex factors contributing to Keytruda's cost, patients and healthcare providers can work together to find solutions that make this life-saving treatment more accessible.

References:

[1] DrugPatentWatch.com
[2] Centers for Medicare and Medicaid Services (CMS). (2022). Medicare Coverage of Immunotherapy.
[3] National Cancer Institute (NCI). (2022). Pembrolizumab.
[4] National Institute for Health and Care Excellence (NICE). (2022). Pembrolizumab for treating adult and adolescent patients with melanoma that is advanced or has spread.

Note: The annual cost mentioned in the text may fluctuate with price updates.